Journals / Medicine Science / 2013 / Cilt: 2 Sayı: 1

Adjuvant Use of Melatonin with Fluoxetine for Management of Fibromyalgia

Pages
423–435
Publication Date
2013-03-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusion, adjuvant use of melatonin with fluoxetine improves the biochemical and clinical parameters of FMS patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Fibromyalgia (FMS) is a chronic musculoskeletal disorder characterized by generalized muscular pain and tenderness at specific anatomical sites.
📊
Key Findings & Data:A double-blind clinical study was conducted on 45 patients with FMS randomized into 4 groups; group A, treated with fluoxetine 20mg/day alone; group B, treated with melatonin 5mg alone; group C, treated with combination of fluoxetine 20 mg+3 mg melatonin; group D treated with combination of fluoxetine 20 mg+5 mg melatonin.
💡
Conclusion & Impact:In conclusion, adjuvant use of melatonin with fluoxetine improves the biochemical and clinical parameters of FMS patients.
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Fibromyalgia · Oxidative Stress · Serotonin

Abstract

Fibromyalgia (FMS) is a chronic musculoskeletal disorder characterized by generalized muscular pain and tenderness at specific anatomical sites. Although melatonin was effective in treating the pain associated with this syndrome, no defined clinical evidence supports this claim. The present study was designed to evaluate the clinical significance of using melatonin, alone or in combination with fluoxetine in FMS. A double-blind clinical study was conducted on 45 patients with FMS randomized into 4 groups; group A, treated with fluoxetine 20mg/day alone; group B, treated with melatonin 5mg alone; group C, treated with combination of fluoxetine 20 mg+3 mg melatonin; group D treated with combination of fluoxetine 20 mg+5 mg melatonin. Both fluoxetine and melatonin were given once daily in the morning and night time respectively for 8 weeks. Each patient clinically evaluated using Fibromyalgia Impact Questionnaire (FIQ). Serum levels of serotonin, malondialehyde and nitric oxide were also evaluated. Using melatonin (3 and 5mg/day) in combination with 20mg/day fluoxetine significantly decreased total FIQ score values; the combination therapy significantly decreased serum serotonin level associated with reduction in the oxidative stress parameters (MDA and NO). In conclusion, adjuvant use of melatonin with fluoxetine improves the biochemical and clinical parameters of FMS patients.

🔖

Cite This Article

Hussain, S. A., ALKHALİFA, İ. İ., JASSİM, N. A., HUSSAİN, S. A., ALKHALİFA, İ. İ., JASSİM, N. A. (2013). Adjuvant Use of Melatonin with Fluoxetine for Management of Fibromyalgia. Medicine Science, Cilt: 2 Sayı: 1, 423–435. https://ajindex.com/articles/1003325

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Koopman WJ, Boulware DW, Gustavo R, Heudebert GR. Fibromyalgia; Clinical Primer of Rheumatology, Lippincott Williams and Wilkins, Philadelphia; 2003; 226-35.
  2. White KP, Speechley M, Harth M. The London FMS Epidimiology Study: The prevalence of FMS in London. J Rheumatol 1999; 26:1570-6.
  3. Erin L, Rose RL, Allghanbari V. A review of fibromyalgia and its treatment. Drug Topics 2005; 11:38-48.
  4. Rao SG, Gendreau JF, Kranzler JD. Understanding the fibromyalgia syndrome. Psychopharmacol Bull 2008; 40:24-56. Goldenberg L. Fibromyalgia and related syndromes, Choochberg M, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, (eds); Textbook of Practical Rheumatology, (3 rd ed), 2004:255-66.
  5. Elide PK, Hole K. Interaction between serotonin and substance P in the regulation of nociception. Brain Res 1991; 550:225-30.
  6. Russell JM, Michalek JE, Vipraio GA. Platelets 3H-impramine uptake receptor density and serum serotonin levels in patients with FMS. J Rheumatol 1992; 19:104-9. Russell IJ. The neurochemical pathogenesis of fibromyalgia syndrome. J Musculoskel Pain 1996; 4:61-92.
  7. Ozgocmen S, Ozyurt H. Antioxidant status, lipid peroxidation and nitric oxide in fibromyalgia: etiologic and therapeutic concerns. Rheumatol Int 2005; 10:1-6.
  8. Mclver KL, Evans C. NO-mediated alterations in skeletal muscle nutritive blood flow and lactate metabolism in fibromyalgia. Pain 2006; 120:161-9. Mense S. Neurobiological basis of muscle pain. Schmerz 1999; 13:3-17. Pall ML. Common etiology of posttraumatic stress disorder, fibromyalgia, chronic fatigue syndrome, and multiple chemical sensitivity via elevated nitric oxide/peroxynitrite. Med Hypoth 2001; 57:139-45.
  9. Zhang H, Akbar M, Kim HY. Melatonin: an endogenous negative modulator of 1 2lipoxygenase in the rat pineal gland. Biochem J 1999; 344:487-93.
  10. Storr M, Koppitz P, Sibaev A. Melatonin reduces non- adrenergic, non-cholinergic relaxant neurotransmission by inhibition of nitric oxide synthase activity in the gastrointestinal tract of rodents in vivo. J Pineal Res 2002; 33:101-8.
  11. Vural H, Sabuncu T, Arslan SO, Aksoy N. Melatonin inhibits lipid peroxidation and stimulates the antioxidant status of diabetic rats. J Pineal Res 2001; 31:193-8.
  12. Cuzzocrea S, Constantino G, Mazzon E, Caputi AP. Regulation of prostaglandin production in carrageenan-induced pleurisy by melatonin. J Pineal Res 1999; 27:9-14.
  13. Reiter RJ, Tan DX, Burkhardt S. Reactive oxygen and nitrogen species and cellular and organismal decline: amelioration with melatonin. Mech Age Devel